Evommune (EVMN) Common Equity (2024 - 2026)
Evommune (EVMN) reported Common Equity of $304.6 million for Q1 2026, up 292.47% year-over-year from $77.6 million in Q1 2025, and up 48.15% on a QoQ basis from $205.6 million in Q4 2025.
Evommune (EVMN) has 3 years of Common Equity data on file, last reported at $304.6 million in Q1 2026.
- Quarterly Common Equity rose 292.47% year-over-year to $304.6 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $304.6 million (up 292.47% YoY) and the FY2025 annual result came in at $205.6 million, up 242.52% from the prior year.
- Common Equity rose to $304.6 million in Q1 2026 per EVMN's latest filing, from $205.6 million in the prior quarter.
- Across five years, Common Equity topped out at $304.6 million in Q1 2026 and bottomed at -$183.1 million in Q3 2025.
- The 3-year median for Common Equity is -$133.4 million (2024), against an average of -$16.3 million.
- The widest annual swing landed in 2025, when Common Equity slumped 49.47%; it then surged 292.47% in 2026.
- Tracing EVMN's Common Equity over 3 years: stood at -$144.2 million in 2024, then surged by 242.52% to $205.6 million in 2025, then soared by 48.15% to $304.6 million in 2026.
- Per Business Quant, the three latest EVMN Common Equity figures stand at $304.6 million (Q1 2026), $205.6 million (Q4 2025), and -$183.1 million (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Common Equity (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | -1.42 Mn |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | 35.63 Mn |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | 1.00 Bn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | 14.38 Mn |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 19.36 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | 13.21 Mn |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 31.42 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 1.08 Bn |
| 10 | Evommune | 744.11 Mn | 532.65 Mn | - | 304.56 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 304.56 Mn |
| Dec 31, 2025 | 205.57 Mn |
| Sep 30, 2025 | -183.14 Mn |
| Mar 31, 2025 | -158.24 Mn |
| Dec 31, 2024 | -144.24 Mn |
| Sep 30, 2024 | -122.53 Mn |